American Surgical Association
ASA Main
Home
Meeting
Home
Preliminary
Program
Registration
Information
Hotel & Area
Information
Optional
Tour
Past & Future Meetings

Search Meeting

Back to 2017 Program


Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534). A Report From the Children's Oncology Group.
Peter F Ehrlich1, Murali Chintagumpala2, Yuen Chi3, Fred Hoffer4, Elizabeth Pearlman5, John Kalapurakal6, Anne Warwick7, Robert C Shamberger8, Geetika Khanna9, Arnold Paulino10, Eric Gratias11, Elizabeth Mullen12, James Geller13, Jeff Dome14, Michael Ritchey15
1University of Michigan, Ann Arbor, MI;2MD Anderson Baylor, Houston, TX;3University of Florida, Gainesville, FL;4University of Washington, Seattle, WA;5Luire Childrens Hospital, Chicago, IL;6Northwestern, Chicago, IL;7Walter Reed Medical Center, Washinton, DC;8Boston Childrens and Harvard University, Boston, MA;9University of Washington at St Louis, St Louis, MO;10Md Anderson, Houston, TX;11Childrens Oncology Group, Atlanata, GA;12Dana Farber and Boston Childrens Hopsital, Boston, MA;13University of Cincinnati, Cincinnati, OH;14Children National Medical Center, Washington DC, DC;15Phoenix Childrens Hosptial, Phoenix, AZ

OBJECTIVE(S): No prospective therapeutic clinic trials in children with bilateral Wilms tumors (BWT) exist. Historical outcomes for this group were poor and often involved prolonged chemotherapy; on NWTS-5, 4-year event-free-survival (EFS) and overall-survival (OS) were 61% and 80%. The Children’s Oncology Group (COG) study ARENO534 aimed to improve EFS and OS while preserving renal tissue by intensifying pre-operative chemotherapy completing definitive surgery by 12 weeks from diagnosis and modifying post-operative chemotherapy based on histologic response
METHODS:Patients were enrolled and imaging studies were centrally reviewed to assess for bilateral lesions. Patients with BWT were treated with 3-drug induction chemotherapy (vincristine, dactinomycin and doxorubicin) for 6 or 12 weeks based on radiographic response followed by surgery and further chemotherapy determined by histologic response. Radiation therapy was provided for post-chemotherapy stage III disease
RESULTS: 194/208 patients were evaluable. 4-year EFS and OS were 80.97% (95% CI: 70.98%-90.96%) and 94.16% (95% CI: 88.40%-99.92%). 25 patients relapsed and 7 had disease progression. After induction chemotherapy 163/194 (84.02%) underwent definitive surgical treatment in at least one kidney by 12 weeks and 39% retained parts of both kidneys. Surgical approaches included: unilateral total nephrectomy with contralateral partial nephrectomy (48%), bilateral partial nephrectomy (35%), unilateral total nephrectomy (10.5%), unilateral partial nephrectomy (4%) and bilateral total nephrectomies (2.5%)
CONCLUSIONS: The AREN0534 treatment approach including standardized three-drug preoperative chemotherapy, surgical resection within 12 weeks of diagnosis and response-based post-operative therapy improved EFS and OS and preservation of renal parenchyma compared to historical outcomes for children with BWT.


Back to 2017 Program


Philly Skyline Love Park Betsy Ross Tribute Love Statue